^
Association details:
| Biomarker: | BCR-ABL1 G250E |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Treatment recommendations based on BCR-ABL1 mutation profile…Nilotinib…Contraindicated mutations...T315I, Y253H, E255K/V, or F359V/C/I or G250E.
